title: Omalizumab under 12 years old: real-life practice.
authors.forename: H
authors.initials: H
authors.lastname: Pite
authors.forename: Â
authors.initials: Â
authors.lastname: Gaspar
authors.forename: M
authors.initials: M
authors.lastname: Paiva
authors.forename: P
authors.initials: P
authors.lastname: Leiria-Pinto
mesh_terms: D000485:Allergens / Q000009:adverse effects / Q000276:immunology; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D006760:Hospitalization; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology / Q000378:metabolism; D007223:Infant; D008297:Male; D000069444:Omalizumab; D052638:Particulate Matter / Q000009:adverse effects; D039981:Pyroglyphidae; D011788:Quality of Life; D012129:Respiratory Function Tests; D016896:Treatment Outcome
chemical_list: D000485:Allergens; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D052638:Particulate Matter; D000069444:Omalizumab; D007073:Immunoglobulin E